Raloxifene enhances vertebral mechanical properties independent of bone density

Bone

Volumn 39, Issue 5, 2006, Pages 1130-1135

  Allen, Matthew R ^a   Iwata, Ken ^a   Sato, Masahiko ^a,c   Burr, David B ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Biomechanics; Bisphosphonates; Microdamage; Osteoporosis; SERMS

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; RALOXIFENE; RISEDRONIC ACID; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BIOMECHANICS; BONE DENSITY; BONE INJURY; BONE MINERAL; BONE MINERALIZATION; BONE STRENGTH; BONE TURNOVER; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG EFFICACY; FEMALE; MECHANICAL STRESS; MORPHOMETRICS; NONHUMAN; PHARMACODYNAMICS; VERTEBRA FRACTURE;

ABSORPTIOMETRY, PHOTON; ANIMALS; BIOMECHANICS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DENSITOMETRY, X-RAY; DIPHOSPHONATES; DOGS; DRUG ADMINISTRATION SCHEDULE; FEMALE; LUMBAR VERTEBRAE; RALOXIFENE; SPINE;

EID: 33749537051     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.05.007     Document Type: Article

References (30)

1. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 (1996) 1535-1541
2. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
3. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282 (1999) 1344-1352
4. Reginster J., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11 (2000) 83-91
5. Chesnut III C.H., Silverman S., Andriano K., Genant H., Gimona A., Harris S., et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 109 (2000) 267-276
6. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282 (1999) 637-645
7. Delmas P.D., and Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 34 (2004) 599-604
8. Hui S.L., Slemenda C.W., and Johnston Jr. C.C. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81 (1988) 1804-1809
9. Kanis J.A., Johnell O., Oden A., Dawson A., De Laet C., and Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12 (2001) 989-995
10. De Laet C.E., van Hout B.A., Burger H., Hofman A., and Pols H.A. Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ 315 (1997) 221-225
11. Sarkar S., Mitlak B.H., Wong M., Stock J.L., Black D.M., and Harper K.D. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17 (2002) 1-10
12. Cummings S.R., Karpf D.B., Harris F., Genant H.K., Ensrud K., LaCroix A.Z., et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112 (2002) 281-289
13. Li Z., Meredith M.P., and Hoseyni M.S. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 20 (2001) 3175-3188
14. Watts N.B., Cooper C., Lindsay R., Eastell R., Manhart M.D., Barton I.P., et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 7 (2004) 255-261
15. Burr D.B., and Hooser M. Alterations to the en bloc basic fuchsin staining protocol for the demonstration of microdamage produced in vivo. Bone 17 (1995) 431-433
16. Mashiba T., Turner C.H., Hirano T., Forwood M.R., Johnston C.C., and Burr D.B. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28 (2001) 524-531
17. Martin B., Fyhrie D.P., and Yeh O.C. Sampling bones for microcracks. Trans Orthop Res Soc 30 (2005) [Abstract 1540]
18. Parfitt A., Drezner M., Glorieux F., Kanis J., Malluche H., Meunier P., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 2 (1987) 595-610
19. Huja S.S., Hasan M.S., Pidaparti R., Turner C.H., Garetto L.P., and Burr D.B. Development of a fluorescent light technique for evaluating microdamage in bone subjected to fatigue loading. J Biomech 32 (1999) 1243-1249
20. Jackson S., James M., and Abrams P. The effect of oestradiol on vaginal collagen metabolism in postmenopausal women with genuine stress incontinence. BJOG 109 (2002) 339-344
21. Moro L., Bettica P., Romanello M., and Suarez K.N. 17 beta-Estradiol and tamoxifen prevent the over-glycosylation of rat trabecular bone collagen induced by ovariectomy. Eur J Clin Chem Clin Biochem 35 (1997) 29-33
22. Paschalis E.P., Boskey A.L., Kassem M., and Eriksen E.F. Effect of hormone replacement therapy on bone quality in early postmenopausal women. J Bone Miner Res 18 (2003) 955-959
23. Khastgir G., Studd J., Holland N., Alaghband-Zadeh J., Sims T.J., and Bailey A.J. Anabolic effect of long-term estrogen replacement on bone collagen in elderly postmenopausal women with osteoporosis. Osteoporos Int 12 (2001) 465-470
24. Wu P., Koharski C., Nonnenmann H., and Vashishth D. Loading of non-enzymatically glycated and damaged bone results in an instantaneous fracture. Trans Orthop Res Soc 28 (2003) 404
25. Vashishth D., Wu P., and Gibson G. Age-related loss in bone toughness is explained by non-enzymatic glycation of collagen. Trans Orthop Res Soc 29 (2004)
26. Boxberger J., and Vashishth D. Nonenzymatic glycation affects bone fracture by modifying creep and inelastic properties of collagen. Trans Orthop Res Soc 29 (2004)
27. Tang S., Sharan A., Novak E., Ford T., and Vashishth D. Nonenzymatic glycation causes loss of toughening mechanisms in human cancellous bone. Trans Orthop Res Soc 30 (2005)
28. Viguet-Carrin S., Roux J.P., Arlot M.E., Gineyts E., Duboeuf F., Merabet Z., et al. Contribution of the advanced glycation end product pentosidine to compressive biomechancial properties of human lumbar vertebrae. J Bone Miner Res 20 (2005) S115
29. Hernandez C.J., Tang S.Y., Baumbach B.M., Hwu P.B., Sakkee A.N., van der Ham F., et al. Trabecular microfracture and the influence of pyridinium and non-enzymatic glycation-mediated collagen cross-links. Bone 37 (2005) 825-832
30. Wang X., Shen X., Li X., and Agrawal C.M. Age-related changes in the collagen network and toughness of bone. Bone 31 (2002) 1-7